Shares of RAPT Therapeutics (RAPT) plunged 46% Monday after the company said it was scrapping development of its drug ...
"RAPT Therapeutics shares tumble by 48% after zelnecirnon programme cull" was originally created and published by Clinical ...
RAPT Therapeutics has ended its zelnecirnon program following safety concerns raised by the FDA after a severe adverse event ...
Removing zelnecirnon means the biotech’s sole remaining clinical-stage asset is tivumecirnon, a phase 2 oncology med being ...
As previously reported, JPMorgan analyst Anupam Rama downgraded Rapt Therapeutics (RAPT) to Underweight from Neutral after the company announced the discontinuation of the zelnecirnon program in ...
Additionally, we continue to actively pursue in-licensing opportunities for clinical-stage assets.” About RAPT Therapeutics, Inc. RAPT Therapeutics is a clinical-stage, immunology-based therapeutics ...
Shares of RAPT Therapeutics touched an all-time low following news the company terminated its zelnecirnon program after feedback from the Food and Drug Administration. In the last hour of Monday's ...
Shares of RAPT Therapeutics (NASDAQ:RAPT) plunged 44% in early trading Monday after the company said it was scrapping ...
In February 2024, the FDA put two Phase II studies of zelnecirnon under a clinical hold after a case of liver failure was deemed potentially related to the drug.
RAPT Therapeutics stock falls after halting its zelnecirnon program following FDA clinical hold. Company shifts focus.
The South San Francisco, Calif., biopharmaceutical company in May shut down two trials of zelnecirnon, which was being evaluated as a treatment for asthma and atopic dermatitis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback